

Key Sanochemia Group Data in T€

Performance data	Q1	Q2	Q3	Q1-Q3	Q1-Q3	Change as %	2004/05	2003/04
	2005/06	2005/06	2005/06	2005/06	2004/05		2004/05	2003/04
	Oct.05-Dec.05	Jan.06-Mar.06	Apr.06-Jun.06	Oct.05-Jun.06	Oct.04-Jun.05	Oct.04-Sep.05	Oct.03-Sep.04	
Sales revenues	7,174	9,196	6,619	22,989	22,250	3%	28,927	25,798
<i>Sales&Marketing (Human Pharmaceuticals)</i>	2,883	3,156	3,112	9,151	8,717	5%	11,469	9,758
<i>Production</i>	4,291	3,588	3,507	11,386	13,521	-16%	17,452	15,982
<i>R&D</i>	0	2,452	0	2,452	2	122500%	4	58
<i>Reconciliation</i>	0	0	0	0	10	0%	2	0
EBITDA	1,314	2,301	1,217	4,832	6,009	-20%	7,524	2,968
Depreciation / amortisation	-949	-993	-897	-2,839	-2,935	3%	-4,034	-4,618
EBIT	365	1,308	320	1,993	3,074	-35%	3,490	-1,650
<i>Sales&Marketing (Human Pharmaceuticals)</i>	179	333	73	585	386	52%	449	-1,654
<i>Production</i>	1,240	739	334	2,313	6,034	-62%	7,561	4,823
<i>R&D</i>	-349	1,435	20	1,106	-1,589	-	-2,105	-1,941
<i>Reconciliation</i>	-705	-1,199	-107	-2,011	-1,757	-14%	-2,415	-2,878
Financial result	1,063	-157	-2,320	-1,414	3,464	-	4,372	935
Pre-tax profit / loss	1,428	1,151	-2,000	579	6,538	-91%	7,862	-716
Net profit / loss	1,024	993	-1,729	288	4,993	-94%	5,648	-1,858
Earnings / losses per share	0.11	0.10	-0.17	0.04	0.48	-92%	0.56	-0.18
Structural data				2005/06	2004/05	Change as %	2004/05	2003/04
				30.06.2006	30.06.2005		30.09.2005	30.09.2004
Balance sheet total				106,800	83,411	28%	91,031	74,747
Tangible assets				16,298	16,872	-3%	16,567	17,282
Intangible assets				20,498	17,937	14%	18,570	17,677
Shareholders' equity				59,176	58,108	2%	58,784	53,142
Equity ratio				55.4%	69.7%	-20%	64.6%	71.1%
IFRS Cash flow				Q1-Q3 2005/06	Q1-Q3 2004/05	Change as %	2004/05	2003/04
				Oct.05-Jun.06	Oct.04-Jun.05		Oct.04-Sep.05	Oct.03-Sep.04
Cash flow from operating activities				5,814	11,539	-50%	16,460	5,159
Cash flow from investment activity				-4,124	-4,807	14%	-14,046	-5,411
Cash flow from financing activity				3,428	-1,926	-	4,917	-593

Some minor changes may be due to rounding cumulative figures.
Due to the application of new IFRS guidelines, it was necessary to restate the figure of the previous year.